Comparative pathogenicity of type 1 and type 2 isolates of porcine reproductive and respiratory syndrome virus (PRRSV) in a young pig infection model

Martínez-Lobo, Francisco Javier; Díez-Fuertes, Francisco; Segalés, Joaquím; Garcı́a-Artiga, Carlos; Simarro, I.; Castro, José María Albertos; Prieto, C.

doi:10.1016/j.vetmic.2011.06.025

Cited by 75 publications

(61 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding the challenge strain 3267, when used in previous experiments (Díaz et al, 2012) it was shown that most animals developed a viremia long enough to cover the entire exposure phase, being thus adequate for the purpose of the present study. The results of the infection with strain 3267 can be considered as typical of an average genotype 1 subtype 1 isolate when inoculated in young pigs (Martínez-Lobo et al, 2011). It is difficult to speculate what would have happened using a different heterologous strain but it is reasonable to think that virulence and antigenic similarity would play a role.…”

Section: Discussionmentioning

confidence: 99%

“…In contrast, vaccination of piglets is more controversial. Firstly, because respiratory disease caused by PRRSV, particularly by genotype 1 isolates, is not always overt (Martínez-Lobo et al, 2011) and depends on the interaction with other pathogens (Van Gucht et al, 2004). Therefore, the beneficial effect of vaccination is more difficult to evaluate.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vaccination with a genotype 1 modified live vaccine against porcine reproductive and respiratory syndrome virus significantly reduces viremia, viral shedding and transmission of the virus in a quasi-natural experimental model

Pileri

Gibert

Soldevila

et al. 2015

Veterinary Microbiology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Vaccination with a genotype 1 modified live vaccine against porcine reproductive and respiratory syndrome virus significantly reduces viremia, viral shedding and transmission of the virus in a quasi-natural experimental model

Pileri

Gibert

Soldevila

et al. 2015

Veterinary Microbiology

View full text Add to dashboard Cite

“…To our knowledge, this is the first experimental challenge study to evaluate and compare two commercial type 1 PRRSV-based modified live vaccines against heterologous type 1 and type 2 PRRSV challenge. The lack of cross-protection of the type 1 PRRSV-based modified live vaccine against type 2 PRRSV challenge is clinically significant information because type 2 PRRSV induces more severe respiratory disease than type 1 PRRSV (14,29,30). Nonetheless, the antigenic diversity of the field strains of both genotypes is extreme, and the outcome of vaccination with type 1 PRRSV-based modified live vaccines is difficult to predict.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Two Commercial Type 1 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Modified Live Vaccines against Heterologous Type 1 and Type 2 PRRSV Challenge in Growing Pigs

Kim

Park

Choi

et al. 2015

Clin Vaccine Immunol

View full text Add to dashboard Cite

The objective of the present study was to compare the efficacy of two commercial type 1 porcine reproductive and respiratory syndrome virus (PRRSV) modified live vaccines against heterologous type 1 and type 2 PRRSV challenge in growing pigs. Vaccination with a type 1 PRRSV vaccine reduced the level of viremia after type 1 PRRSV challenge but did not reduce the level of viremia after the type 2 PRRSV challenge in pigs. Increased levels of interleukin-10 (IL-10) stimulated by type 2 PRRSV coincided with the low numbers of type 2 PRRSV-specific interferon gamma-secreting cells (IFN-␥-SC) in vaccinated pigs after type 2 PRRSV challenge, whereas low levels of IL-10 stimulated by type 1 PRRSV coincided with high numbers of type 1 PRRSV-specific IFN-␥-SC in vaccinated pigs after type 1 PRRSV challenge. Additionally, vaccination with the type 1 PRRSV vaccine effectively reduced the lung lesions and type 1 PRRSV nucleic acids in type 1 PRRSV-challenged pigs but did not reduce lung lesions and type 2 PRRSV nucleic acids in type 2 PRRSV-challenged pigs. There were no significant differences between two commercial type 1 PRRSV vaccines against type 1 and type 2 PRRSV challenge based on virological results, immunological responses, and pathological outcomes. This study demonstrates that vaccinating pigs with the type 1 PRRSV vaccine provides partial protection against respiratory disease with heterologous type 1 PRRSV challenge but no protection with heterologous type 2 PRRSV challenge. P orcine reproductive and respiratory syndrome (PRRS), caused by PRRS virus (PRRSV), is one of the most economically devastating diseases facing pig production worldwide. The infection of growing pigs with PRRSV causes severe respiratory diseases, leading to impaired growth in postweaned and growing pigs (1). The virus can also give rise to reproductive failure in sows (1). PRRSV is a small, positive-sense, enveloped, single-stranded RNA virus belonging to the family Arteriviridae in the order Nidovirales (2). PRRSV is classified into type 1 (European) and type 2 (North American) genotypes based on the 3=-terminal structural genes or the entire genome (3, 4). Type 1 PRRSV is further divided into three subtypes: a pan-European subtype 1 and East European subtypes 2 and 3, with nucleocapsid protein sizes of 128, 125, and 124 amino acids, respectively (5).In South Korea, type 2 PRRSV was first isolated in 1994 (6). Until 2005, only type 2 PRRSV was detected in Korean swine herds (7,8 Since the first introduction of type 1 PRRSV vaccines, crossprotection is a major clinical issue because of the coexistence of the type 1 and type 2 PRRSVs in swine herds. Previous crossprotection studies have provided inconsistent results (11, 12). The Porcilis PRRS vaccine (MSD Animal Health) provides no protection against heterologous type 2 PRRSV challenge (11), whereas the Amervac PRRS vaccine (Hipra) provides partial protection against heterologous type 2 PRRSV challenge (12). However, a comparison of two commercial type 1 PRRSV-based modified live vaccines a...

show abstract

“…The deparaffinized lung sections were stained with hematoxylin and eosin (Sigma) for histopathology. The lung sections were examined for the severity of interstitial pneumonia as described elsewhere (Halbur et al, 1995;Martínez-Lobo et al, 2011).…”

Section: Histopathology Of the Lungsmentioning

confidence: 99%

Pathogenicity and genetic characteristics associated with cell adaptation of a virulent porcine reproductive and respiratory syndrome virus nsp2 DEL strain CA-2

Lee

Choi²,

Nam³

et al. 2016

Veterinary Microbiology

View full text Add to dashboard Cite

Comparative pathogenicity of type 1 and type 2 isolates of porcine reproductive and respiratory syndrome virus (PRRSV) in a young pig infection model

Cited by 75 publications

References 34 publications

Vaccination with a genotype 1 modified live vaccine against porcine reproductive and respiratory syndrome virus significantly reduces viremia, viral shedding and transmission of the virus in a quasi-natural experimental model

Vaccination with a genotype 1 modified live vaccine against porcine reproductive and respiratory syndrome virus significantly reduces viremia, viral shedding and transmission of the virus in a quasi-natural experimental model

Comparison of Two Commercial Type 1 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Modified Live Vaccines against Heterologous Type 1 and Type 2 PRRSV Challenge in Growing Pigs

Pathogenicity and genetic characteristics associated with cell adaptation of a virulent porcine reproductive and respiratory syndrome virus nsp2 DEL strain CA-2

Contact Info

Product

Resources

About